Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have divulged E3 ubiquitin-protein ligase CBL-B (CBLB) inhibitors reported to be useful for the treatment of cancer.

Oita University has synthesized tricyclic heterocyclic compounds reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

TYK Medicines Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently bonded to an EGFR (mutant)-targeting moiety through a linker.

Icagen Inc. has disclosed potassium voltage-gated channel subfamily KQT member 2 (KCNQ2; Kv7.2) activators reported to be useful for the treatment of pain, Alzheimer’s disease, epilepsy, motor neuron disease, neurodevelopmental disorders, depression, tinnitus and attention deficit hyperactivity disorder, among others.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has divulged DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has described pyrrolobenzodiazepine compounds reported to be useful for the treatment of cancer.

Amgen Inc. has synthesized GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Genzyme Corp. (Sanofi Genzyme) has identified receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis and Parkinson’s disease.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Genesis Therapeutics Inc. has divulged phosphatidylinositol 3-kinase alpha (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.